FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

PD Cheverton

Research Profile

Chemicals & Drugs

Procedures

Infusions, Intravenous

Concepts & Ideas

Physiology

Geographic Areas

Disorders

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Andrew R Clamp; M Adams; R Atkinson; E Boven; A Hilary Calvert; A Cervantes; Trivadi Ganesan; J Lotz; Paul A Vasey; PD Cheverton; Gordon C Jayson
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Jeremy P Braybrooke; M Ranson; C Manegold; K Mattson; N Thatcher; PD Cheverton; M Sekiguchi; M Suzuki; R Oyama; Denis C Talbot
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Jeremy P Braybrooke; Epie Boven; Nicholas Bates; Rita Ruijter; Nicola A Dobbs; PD Cheverton; HERBERT PINEDO; Denis C Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of PD Cheverton (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2004: Andrew R Clamp; M Adams; R Atkinson; E Boven; A Hilary Calvert; A Cervantes; Trivadi Ganesan; J Lotz; Paul A Vasey; PD Cheverton; Gordon C Jayson
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Gynecologic oncology 2004;95(1):114-9.
2003: Jeremy P Braybrooke; M Ranson; C Manegold; K Mattson; N Thatcher; PD Cheverton; M Sekiguchi; M Suzuki; R Oyama; Denis C Talbot
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41(2):215-9.
2003: Jeremy P Braybrooke; Epie Boven; Nicholas Bates; Rita Ruijter; Nicola A Dobbs; PD Cheverton; HERBERT PINEDO; Denis C Talbot
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):913-21.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.